Cancer associated antigen CA19-9 in colonic effluent of patients with neoplasia of the colon and inflammatory bowel disease.
We measured colonic effluent samples from 10 patients with colorectal cancer, 13 with adenomatous polyps, 14 with normal colons and compared them to 10 patients with inflammatory bowel disease by measuring this CA19-9 content. Results showed considerable overlap between the different pathologic categories, making differentiation impossible. A lower level of CA19-9 in the effluent samples from patients with adenomas was noted. These differences were reproducible for assays performed several months apart. CA19-9 may originate from the upper gastrointestinal tract since large amounts are present in pancreatico-biliary secretions. This antigen is therefore not useful in the diagnosis of neoplasia or inflammatory bowel disease using colonic effluent samples as the test material.
Tobi
M
M
Department of Gastroenterology, Tel-Aviv Medical Center, Israel.
Steinberg
W
W
Henry
J
J
Nochomovitz
L
L
D000328:Adult; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D001826:Body Fluids / Q000276:immunology; D003110:Colonic Neoplasms / Q000276:immunology*; D003111:Colonic Polyps / Q000276:immunology*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000276:immunology*; D007419:Intestinal Secretions / Q000276:immunology; D008875:Middle Aged
D015295:Antigens, Tumor-Associated, Carbohydrate